Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 394-400

  Kuznetsova, Natalia R ^a   Sevrin, Chantal ^b   Lespineux, David ^b   Bovin, Nicolai V ^a   Vodovozova, Elena L ^a   Mészáros, Tamás ^c   Szebeni, Janos ^c   Grandfils, Christian ^b  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Coagulation tests; Complement activation; Hemocompatibility; Lipophilic prodrugs; Liposomes

Indexed keywords

CONCENTRATION-DEPENDENT; DRUG DELIVERY SYSTEM; HEMOCOMPATIBILITY; HUMAN BLOODS; IN-VITRO TESTS; LIPOSOMAL FORMULATION; MELPHALAN; NANO-SIZED; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; POTENTIAL VALUES; PRODRUGS; RED BLOOD CELL; SIALYL LEWIS X; TETRASACCHARIDES; UNDESIRABLE EFFECTS; WHOLE BLOOD;

BLOOD; COAGULATION; DRUG DELIVERY; LIPID BILAYERS; LOADING; ZETA POTENTIAL;

LIPOSOMES;

1,2 DIOLEOYLGLYCERIDE ESTER; COMPLEMENT; ESTER DERIVATIVE; LIPOSOME; MELPHALAN; METHOTREXATE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PRODRUG; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD COMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ERYTHROCYTE; HEMOLYSIS; HUMAN; INCUBATION TEMPERATURE; LIPID BILAYER; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE; ZETA POTENTIAL;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; COMPLEMENT ACTIVATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HEMOLYSIS; HUMANS; LIPID BILAYERS; LIPOSOMES; MELPHALAN; METHOTREXATE; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLINOSITOLS; PRODRUGS; SURFACE PROPERTIES;

EID: 84861670556     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.010     Document Type: Article

References (51)

1. T. Lammers, W.E. Hennink, and G. Storm Tumour-targeted nanomedicines: principles and practice Br. J. Cancer 99 2008 392 397
2. L. Harris, G. Batist, R. Belt, D. Rovira, R. Navari, N. Azarnia, L. Welles, and E. Winer Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 2002 25 36
3. D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 1999 691 743
4. D. Northfelt, B. Dezube, J. Thommes, B. Miller, M. Fischl, A. Friedman-Kien, L.D. Kaplan, C. Du Mond, R.D. Mamelok, and D.H. Henry Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J. Clin. Oncol. 16 1998 2445 2451
5. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436
6. M. Coimbra, B. Isacchi, L. van Bloois, J.S. Torano, A. Ket, X. Wu, F. Broere, J.M. Metselaar, C.J.F. Rijcken, G. Storm, R. Bilia, and R.M. Schiffelers Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes Int. J. Pharm. 2011 1 10
7. J.M. Koziara, J.J. Oh, W.S. Akers, S.P. Ferraris, and R.J. Mumper Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles Pharm. Res. 22 2005 1821 1828
8. M.A. Dobrovolskaia, A.K. Patri, J. Zheng, J.D. Clogston, N. Ayub, P. Aggarwal, B.W. Neun, J.B. Hall, and S.E. McNeil Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles Nanomedicine 5 2009 106 117
9. A. Mayer, M. Vadon, B. Rinner, and A. Novak The role of nanoparticle size in hemocompatibility Toxicology 258 2009 139 147
10. N. Gulati, R. Rastogi, A.K. Dinda, R. Saxena, and V. Koul Characterization and cell material interactions of PEGylated PNIPAAM nanoparticles Colloids Surf. B Biointerfaces 79 2010 164 173
11. B.C. Dash, G. Réthoré, M. Monaghan, K. Fitzgerald, W. Gallagher, and A. Pandit The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility Biomaterials 31 2010 8188 8197
12. M.R. Rekha, and C.P. Sharma Hemocompatible pullulan-polyethyleneimine conjugates for liver cell gene delivery: in vitro evaluation of cellular uptake, intracellular trafficking and transfection efficiency Acta Biomater. 7 2011 370 379
13. E. Cenni, D. Granchi, S. Avnet, C. Fotia, M. Salerno, D. Micieli, M.G. Sarpietro, R. Pignatello, F. Castelli, and N. Baldini Biocompatibility of poly (D, L-lactide-co-glycolide) nanoparticles conjugated with alendronate Biomaterials 29 2008 1400 1411
14. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822
15. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N. Rafique, C. Alving, and F.M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil (R)): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437
16. J. Szebeni Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity Toxicology 216 2005 106 121
17. S.M. Moghimi, A.J. Andersen, S.H. Hashemi, B. Lettiero, D. Ahmadvand, A.C. Hunter, T.L. Andersen, I. Hamad, and J. Szebeni Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead J. Controlled Release 146 2010 175 181
18. J. Szebeni, F. Muggia, A. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
19. S.M. Moghimi, I. Hamad, T.L. Andresen, K. Jorgensen, and J. Szebeni Methylation of the phosphate oxygen moiety of phospholipid-methoxy (polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production FASEB J. 20 2006 E2057 E2093
20. N. Kuznetsova, A. Kandyba, I. Vostrov, V. Kadykov, G. Gaenko, J. Molotkovsky, and E. Vodovozova Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles J. Drug Del. Sci. Tech. 19 2009 51 59
21. C. Ehrhardt, C. Kneuer, and U. Bakowsky Selectins-an emerging target for drug delivery Adv. Drug Deliver. Rev. 56 2004 527 549
22. I.P. Witz The selectin-selectin ligand axis in tumor progression Cancer Metastasis Rev. 27 2008 19 30
23. E. Vodovozova, E. Moiseeva, and G. Grechko Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLeX, in a mouse mammary adenocarcinoma model Eur. J. Cancer 36 2000 942 949
24. G.P.A. Michanetzis, Y.F. Missirlis, N.P. Rhodes, D.F. Williams, R. Eloy, and W. Lemm Influence of test protocol in determining the blood response to model polymers J. Mater. S. Mater. Med. 13 2002 757 765
25. M.A. Dobrovolskaia, J.D. Clogston, B.W. Neun, J.B. Hall, A.K. Patri, and S.E. McNeil Method for analysis of nanoparticle hemolytic properties in vitro Nano Lett. 8 2008 2180 2187
26. J.F. Krzyzaniak, F.A. Alvarez Núñez, D.M. Raymond, and S.H. Yalkowsky Lysis of human red blood cells. 4. Comparison of in vitro and in vivo hemolysis data J. Pharm. Sci. 86 1997 1215 1217
27. M.A. Dobrovolskaia, and S.E. McNeil Immunological properties of engineered nanomaterials Nat. Nanotechnol. 2 2007 469 478
28. G.V. Pazynina, M.A. Sablina, A.B. Tuzikov, A.A. Chinarev, and N.V. Bovin Synthesis of complex α2-3 sialooligosaccharides, including sulfated and fucosylated ones, using Neu5Acα2-3Gal as a building block Mendeleev Commun. 13 2003 245 248
29. E.L. Vodovozova, G.V. Pazynina, A.B. Tuzikov, I.V. Grechishnikova, and J.G. Molotkovsky The synthesis of photoaffinity neoglycolipid probes as tools for studying membrane lectins Russ. J. Bioorg. Chem. 30 2004 154 160
30. E.L. Vodovozova, P.Y. Nikol'skii, I.I. Mikhalev, and J.G. Molotkovskii Lipid derivatives of sarcolysin, methotrexate and rubomycin Bioorg. Khim. 22 1996 548 556
31. E. Vodovozova, D. Evdokimov, and J.G. Molotkovsky Synthesis of a lipid derivative of the antitumor agent methotrexate Russ. J. Bioorg. Chem. 30 2004 599 601
32. Standard Practice for Assessment of Hemolytic Properties of Materials 2009 ASTM International West Conshohocken, PA
33. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, M. Bodo, R. Bunger, and C.R. Alving The interaction of liposomes with the complement system: In vitro and in vivo assays Methods Enzymol. 373 2003 136 154
34. E.L. Vodovozova, N.R. Kuznetsova, V.A. Kadykov, S.S. Khutsyan, G.P. Gaenko, and Y.G. Molotkovsky Liposomes as nanocarriers of lipid-conjugated antitumor drugs melphalan and methotrexate Nanotechnol. Russ. 3 2008 228 239
35. M.B. Gorbet, and M.V. Sefton Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes Biomaterial 25 2004 5681 5703
36. B. Cerda-Cristerna, H. Flores, A. Pozos-Guillén, E. Pérez, Ch. Sevrin, and Ch. Grandfils Hemocompatibility assessment of poly (2-dimethylamino ethylmethacrylate) (PDMAEMA)-based polymers J. Control. Release 153 2011 269 277
37. E. Yancheva, D. Paneva, D. Danchev, L. Mespouille, P. Dubois, N. Manolova, and I. Rashkov Polyelectrolyte complexes based on (quaternized) poly ((2-dimethyla-mino) ethylmethacrylate): behaviour in contact with blood Macromol. Biosci. 7 2007 940 954
38. C.T. Pham, L.M. Mitchell, J.L. Huang, C.M. Lubniewski, O.F. Schall, J.K. Killgore, D. Pan, S.A. Wickline, G.M. Lanza, and D.E. Hourcade Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces J. Biol. Chem. 286 2011 123 130
39. M. Moghimi, A.J. Andersen, D. Ahmadvand, P.P. Wibroe, T.L. Andresen, and A.C. Hunter Material properties in complement activation Adv. Drug Deliv. Rev. 63 2011 1000 1007
40. M.B. Pedersen, X. Zhou, E.K.U. Larsen, U.S. Sorensen, J. Kjems, J.V. Nygaard, J.R. Nyengaard, R.L. Meyer, T. Boesen, and T. Vorup-Jensen Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation J. Immunol. 184 2010 1931 1945
41. J. Szebeni, L. Baranyi, S. Savay, M. Bodo, D.S. Morse, M. Basta, G.L. Stahl, R. Bünger, and C.R. Alving Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction Am. J. Heart Circ. Physiol. 279 2000 H1319 H1328
42. I. Lynch, T. Cedervall, M. Lundqvist, C. Cabaleiro-Lago, S. Linse, and K.A. Dawson The nanoparticle-protein complex as a biological entity: a complex fluids and surface science challenge for the 21st century Adv. Colloid Interface Sci. 134-135 2007 167 174
43. P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, and S.E. McNeil Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy Adv. Drug Deliver. Rev. 61 2009 428 437
44. D. Walczyk, F.B. Bombelli, M.P. Monopoli, I. Lynch, and K.A. Dawson What the cell sees in bionanoscience J. Am. Chem. Soc. 132 2010 5761 5768
45. T. Cedervall, I. Lynch, S. Lindman, T. Berggård, E. Thulin, H. Nilsson, K.A. Dawson, and S. Linse Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles Proc. Natl. Acad. Sci. U.S.A. 104 2007 2050 2055
46. M.P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F.B. Bombelli, and K.A. Dawson Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles J. Am. Chem. Soc. 133 2011 2525 2534
47. R.R. Schmidt, and G. Thews Human Physiology second ed 1989 Springer-Verlag Berlin
48. P. Roach, D. Farrar, and C.C. Perry Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry J. Am. Chem. Soc. 128 2006 3939 3945
49. B.J. Clarke, H.C. Côté, D.E. Cool, I. Clark-Lewis, H. Saito, R.A. Pixley, R.W. Colman, and R.T.A. MacGillivray Mapping of a putative surface-binding site of human coagulation factor XII J. Biol. Chem. 264 1989 11497 11502
50. R. Schwarzenbacher, K. Zeth, K. Diedchs, A. Gries, G.M. Kostner, P. Laggner, and R. Prassl Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome EMBO J. 18 1999 6228 6239
51. E. Chu, and V.T. DeVita Jr. Physician's Cancer Chemotherapy Drug Manual, 2007 2007 Jones and Bartlett Publishers Sudbury, MA